Oral Cancer
Conditions
Keywords
oral squamous cell carcinoma, neoadjuvant bio-chemotherapy, concurrent bio-radiotherapy, biomarker
Brief summary
Surgical resection followed by concurrent chemoradiotherapy is considered as the standard of care for locally advanced OSCC (LAOSCC). Although the treatment could provide prompt local control, but it is also associated with high incidence of distant failure. Systemic chemotherapy given either before (neoadjuvant) or after (adjuvant) definitive local treatment has been extensively evaluated to improve the clinical outcome in LAOSCC. Regimens of taxane/cisplatin-based combinations have been shown to improve the treatment outcome of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) in neoadjuvant setting. Recently, cetuximab (Erbitux®), a monoclonal antibody against epidermal growth factor receptor (EGFR), has also been proven to be an efficient agent for advanced and/or refractory HNSCC with acceptable toxicity profiles. In current study, we shall evaluate the feasibility, efficacy and safety of a triplet bio-chemotherapy consisting of cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bio-radiotherapy (CBRT) in patients with LAOSCC.
Detailed description
Patients with high-risk, locally advanced (TxN2b\ 3 or T4N0\ 3, M0) OSCC will be eligible. To detect an interested objective response rate (p1) of 80% versus a non-interested response (p0) rate of 60%, with an α and 1-β of 0.05 and 0.2, respectively (two-sided test), including the estimated dropout rate of 10%, a total of 47 patients will be recruited.
Interventions
DRUGCetuximab,Paclitaxel,Cisplatin
Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
Sponsors
China Medical University Hospital
National Cheng-Kung University Hospital
Chi Mei Medical Hospital
Changhua Christian Hospital
Chang Gung Memorial Hospital
National Health Research Institutes, Taiwan
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. High-risk, locally advanced (TxN2b\ 3 or unresectable T4, M0) OSCC 2. Histologically confirmed squamous cell carcinoma 3. Performance status: Eastern Cooperative Oncology Group performance status (ECOG) 0-1 4. age 18 years or older, less than 70 years of age 5. Having signed informed consent 6. Measurable disease by CT or MRI 7. Adequate hematologic, hepatic and renal function
Exclusion criteria
1. Prior radiotherapy for targeted lesions, chemotherapy, EGFR pathway targeting therapy 2. Prior surgery for cancer except for the purpose of diagnostic biopsy 3. Concomitant active 2nd malignancies or disease-free of malignancies \< 3 years before the study except adequately treated in situ cervical cancer, or non-melanoma skin cancer 4. Concomitant anticancer therapies within the past 28 days 5. Severe cardiopulmonary diseases and other systemic disease under poor control 6. Uncontrolled chronic neuropathy 7. Women who are positive of pregnancy, or in breast-feeding 8. Known allergy to any study treatment 9. Legal incapacity 10. Significant disease which, in the investigator's opinion, would exclude the patient from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the overall response rate after completion of the assigned treatment. | 18 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include the response rate after neoadjuvant therapy, progression-free survival, overall survival, biomarker prediction, and toxicity. | >2 years |
Countries
Taiwan
Outcome results
None listed